Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B
The FDA has approved a new drug called Hibsago for chronic hepatitis B, marking the first "functional cure" for the disease. The drug, developed by GSK, suppresses the virus to undetectable levels and keeps it under control after treatment ends. It showed effectiveness in 19% of trial participants, though some side effects were reported.
The FDA approved Hibsago, a drug that offers a functional cure for chronic hepatitis B by suppressing the virus to undetectable levels and maintaining control after treatment ends. It was tested in two phase 3 trials with over 1,800 participants.
This approval provides new treatment options for millions affected by chronic hepatitis B, offering a potential long-term solution that goes beyond managing the virus. It could reduce the need for lifelong medication and lower the risk of severe complications like liver cancer and failure.
The approval represents a significant medical advancement that offers hope and new possibilities for patients, highlighting progress in treating a major global health issue with a focus on long-term health outcomes.
upbeatBytes summarizes in its own words and links to the original publisher — it doesn't host the article.